PD-1 is an important target that is applied to melanoma clinical therapy, and the expression of PD-1 and its ligand PDL-1 in Treg cells or tumor cells protects tumors from immune-mediated rejection and promotes tumor progression (15, 16, 40). This evidence concerns the gene CD274 and melanoma.